Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from…

Continue ReadingTriple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer